Short hairpin RNA targeting of fibroblast activation protein inhibits tumor growth and improves the tumor microenvironment in a mouse model
Open Access
- 31 May 2013
- journal article
- research article
- Published by Korean Society for Biochemistry and Molecular Biology - BMB Reports in BMB Reports
- Vol. 46 (5) , 252-257
Abstract
Fibroblast activation protein (FAP) is a specific serine protease expressed in tumor stroma proven to be a stimulatory factor in the progression of some cancers. The purpose of this study was to investigate the effects of FAP knockdown on tumor growth and the tumor microenvironment. Mice bearing 4T1 subcutaneous tumors were treated with liposome-shRNA complexes targeting FAP. Tumor volumes and weights were monitored, and FAP, collagen, microvessel density (MVD), and apoptosis were measured. Our studies showed that shRNA targeting of FAP in murine breast cancer reduces FAP expression, inhibits tumor growth, promotes collagen accumulation (38%), and suppresses angiogenesis (71.7%), as well as promoting apoptosis (by threefold). We suggest that FAP plays a role in tumor growth and in altering the tumor microenvironment. Targeting FAP may therefore represent a supplementary therapy for breast cancer. [BMB Reports 2013; 46(5): 252-257]Keywords
This publication has 30 references indexed in Scilit:
- Selective gene silencing by viral delivery of short hairpin RNAVirology Journal, 2010
- Argonaute proteins are key determinants of RNAi efficacy, toxicity, and persistence in the adult mouse liverJournal of Clinical Investigation, 2010
- Targeting fibroblast activation protein inhibits tumor stromagenesis and growth in miceJournal of Clinical Investigation, 2009
- Cancer and the tumor microenvironment: a review of an essential relationshipCancer Chemotherapy and Pharmacology, 2008
- Effect of fibroblast activation protein and α2-antiplasmin cleaving enzyme on collagen Types I, III, and IVArchives of Biochemistry and Biophysics, 2007
- Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptakeJournal of Clinical Investigation, 2006
- Unlocking the potential of the human genome with RNA interferenceNature, 2004
- Stromal Antigen Targeting by a Humanised Monoclonal Antibody: An Early Phase II Trial of Sibrotuzumab in Patients with Metastatic Colorectal CancerOncology Research and Treatment, 2003
- What Is the Evidence That Tumors Are Angiogenesis Dependent?JNCI: Journal of the National Cancer Institute, 1990
- Tumors: Wounds That Do Not HealNew England Journal of Medicine, 1986